Diabetes therapies and CVD – Does the ‘how’ matter more than the how much? - PACE-CME

Diabetes therapies and CVD Does the how matter more than the how much

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Phase 3 study with oral semaglutide meets primary endpoint in high-risk T2D
Phase 3 study with oral semaglutide meets primary endpoint in high-risk T2D
ACC.25
Phase 3 study with oral semaglutide meets primary endpoint in high-risk T2D
- Darren K. McGuire, MD
Expert opinion on the SOUL study results
Expert opinion on the SOUL study results
ACC.25
Expert opinion on the SOUL study results
- Gina Lundberg, MD
Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D
Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D
ACC.25
Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D
- Marc Bonaca, MD
SBP target of lower than 120 mmHg reduces risk of CV events in T2DM
SBP target of lower than 120 mmHg reduces risk of CV events in T2DM
AHA 2024
SBP target of lower than 120 mmHg reduces risk of CV events in T2DM
- Shawna Nesbitt, MD